advertisement
Abstract #18345 Published in IGR 3-3
Innovative glaucoma therapy: glaucoma therapy with topical carbonic anhydrase inhibitors
Herkel U; Pfeiffer NOphthalmologe 2001; 98: 929-933
Topical carbonic anhydrase inhibitors have been used since 1995 for medical glaucoma therapy, when dorzolamide was approved. In 2000, a second carbonic anhydrase inhibitor, brinzolamide, became available in most of Europe. Both substances exhibit a comparable intraocular pressure (IOP)-lowering activity, however, the side-effects are somewhat different. In the five years since its introduction, dorzolamide has had a positive risk-benefit-profile. In combination with any other topical agent, carbonic anhydrase inhibitors have an additive effect on the reduction of the IOP. Animal studies suggest that dorzolamide may improve ocular blood flow independent of the IOP; however, the significance for human glaucoma remains to be established. LA: German
Dr U. Herkel, Universitäts-Augenklinik, Johannes Gutenberg-Universität Mainz, Germany. herkel@mail.uni-mainz.de
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
